Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 1 Instances of use of TRIPS flexibilities by SADC countries 2001–2016

From: Patent challenges in the procurement and supply of generic new essential medicines and lessons from HIV in the southern African development community (SADC) region.

Country Year WTO Class Type of flex Product(s) Disease Royalty Executed
Angola 2005 LDC Par7 All meds All NA Y
Lesotho 2004 LDC Par7 ARVs HIV/AIDS NA Y
Lesotho 2006 LDC Par7 All meds All NA Y
Malawi 2004 LDC Par7 All meds All NA Y
Malawi 2005 LDC Par7 ARVs HIV/AIDS NA Y
Mozambique 2005 LDC Par7 ARVs HIV/AIDS NA Y
South Africa 2003 DC CL AZT, 3TC, AZT/3TC, NVP HIV/AIDS up to 5% N
Tanzania 2008 LDC Par7 All Meds All NA Y
Zambia 2004 LDC CL 3TC/D4T/NVP HIV/AIDS 2.5% Y
Zambia 2004 LDC Par7 ARVs + HIV/AIDS + NA Y
Zambia 2006 LDC Par7 ARVs + HIV/AIDS + NA Y
Zimbabwe 2004 DC CL ARVs HIV/AIDS NK Y
Zimbabwe 2003 DC CL ARVs + HIV/AIDS + NK Y
Zimbabwe 2002 DC CL ARVs + HIV/AIDS + NK Y
Zimbabwe 2005 DC CL ARVs + HIV/AIDS NK Y
  1. Par 7 = the LDC transition provision, CL compulsory licence, ARVs antiretroviral medicines, ARV+ antiretroviral medicines and other medicines needed in the treatment of HIV/AIDS, NA not applicable, NK not known